Shigehiro et al. reported that patritumab deruxtecan, an HER3-targeting antibody–drug conjugate, can effectively reache antigen-positive tumor sites and demonstrates similar drug concentrations in adjacent tumor tissues, facilitating the elimination of neighboring tumors through a bystander effect [33]. Here, ERBB3 is linked to neoplasm.